NanoVibronix, Inc. (NAOV) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 18, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NAOV SEC filings page.
NanoVibronix, Inc. (NAOV) reported $2.2M in revenue over the twelve months to Mar 31, 2026, down 18.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue was flat, but 2025 economics deteriorated sharply: product margins collapsed while operating costs and cash needs widened.
The balance sheet expanded dramatically: total assets rose from$3.6M to$41.1M in FY2025, while goodwill reached$29.1M . With current assets at$7.3M and a current ratio of 1.1x, the expansion is not matched by a comparable pool of near-term operating resources.
With revenue essentially flat, gross margin fell from
Cash conversion weakened alongside earnings: operating cash outflow rose from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of NanoVibronix, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
NanoVibronix, Inc. held $4.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $9.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and NanoVibronix, Inc. scores 20/100 among other emerging companies.
NanoVibronix, Inc. had 1M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and NanoVibronix, Inc. scores 8/100 among other emerging companies.
NanoVibronix, Inc. spent $1.8M on research and development in fiscal year 2025, which was 6.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and NanoVibronix, Inc. scores 29/100 among other emerging companies.
NanoVibronix, Inc. reported revenue of $2.6M in fiscal year 2025, against $2.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and NanoVibronix, Inc. scores 50/100 among other emerging companies.
NanoVibronix, Inc.'s operations used $9.4M of cash in fiscal year 2025, against $2.5M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and NanoVibronix, Inc. scores 13/100 among other emerging companies.
NanoVibronix, Inc.'s cash, cash equivalents and investments came to $4.2M at the end of fiscal year 2025, against $7.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and NanoVibronix, Inc. scores 45/100 among other emerging companies.
NanoVibronix, Inc. scores -4.59, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.2M) relative to total liabilities ($7.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
NanoVibronix, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
NanoVibronix, Inc. reported a net loss of $18.2M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
NanoVibronix, Inc. generated $653K in revenue in Q1 2026. This represents a decrease of 36.3% from the same quarter a year earlier. Against the prior quarter it is up 109.3%.
NanoVibronix, Inc.'s EBITDA was -$3.5M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 90.5% from the same quarter a year earlier.
NanoVibronix, Inc. reported -$3.8M in net income in Q1 2026. This represents a decrease of 104.2% from the same quarter a year earlier. Against the prior quarter it is up 70.3%.
Cash & Balance Sheet
NanoVibronix, Inc. recorded an outflow of $4.3M in free cash flow in Q1 2026, representing a cash shortfall after capex. This represents a decrease of 221.1% from the same quarter a year earlier. Against the prior quarter it is down 60.4%.
NanoVibronix, Inc. held $2.2M in cash as of Q1 2026; long-term debt is not reported for that period.
Not reported for Q1 2026.
Margins & Returns
NanoVibronix, Inc.'s gross margin was -8.4% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 44.4 percentage points from the same quarter a year earlier.
NanoVibronix, Inc.'s ROE was -11.9% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is down 6.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 26.4 percentage points.
Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
NanoVibronix, Inc. invested $468K in research and development in Q1 2026. This represents a decrease of 11.7% from the same quarter a year earlier. Against the prior quarter it is up 1100.0%.
NanoVibronix, Inc. invested $17K in capex in Q1 2026, funding long-term assets and infrastructure. This represents an increase of 240.0% from the same quarter a year earlier. Against the prior quarter it is down 26.1%.
Not reported for Q1 2026.
NAOV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'25 | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'24 | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $653K-36.3% | $312K-29.7% | $722K+92.0% | $494K-39.5% | $1.0M+11.3% | $444K-62.3% | $376K-17.9% | $817K+177.9% |
| Cost of Revenue | $708K+7.9% | $682K+323.6% | $533K+119.3% | $529K+36.0% | $656K+155.3% | $161K-63.4% | $243K+122.9% | $389K+398.7% |
| Gross Profit | -$55K-114.9% | -$370K-230.7% | $189K+42.1% | -$35K-108.2% | $369K-44.4% | $283K-61.6% | $133K-61.9% | $428K+98.1% |
| R&D Expenses | $468K-11.7% | $39K-88.9% | $221K-11.2% | $972K+419.8% | $530K+338.0% | $352K+467.7% | $249K+654.5% | $187K+434.3% |
| SG&A Expenses | $2.4M+80.0% | $2.6M+134.1% | $1.4M+108.5% | $2.3M+214.5% | $1.3M+41.9% | $1.1M-1.6% | $673K-15.5% | $716K-25.6% |
| Operating Income | -$3.7M-100.4% | -$14.8M-981.3% | -$2.2M-131.6% | -$4.0M-489.9% | -$1.9M-226.1% | -$1.4M-95.2% | -$970K-44.8% | -$674K+33.2% |
| EBITDA | -$3.5M-90.5% | N/A | N/A | N/A | -$1.8M | N/A | N/A | N/A |
| Interest Expense | $36K-32.1% | N/A | $53K+60.6% | $144K+323.5% | $53K+55.9% | $34K+3.0% | $33K-5.7% | $34K+3.0% |
| Income Tax | $33K+120.0% | -$419K-8480.0% | $35K+1066.7% | $62K+1450.0% | $15K+114.3% | $5K-54.5% | $3K0.0% | $4K-69.2% |
| Net Income | -$3.8M-104.2% | -$12.9M-798.1% | $510K+151.1% | -$4.0M-477.2% | -$1.9M-218.4% | -$1.4M-76.0% | -$998K-37.3% | -$688K+35.9% |
| EPS (Basic) | -$6.88+77.0% | N/A | -$0.91+74.4% | -$1.03+96.2% | -$29.90-1356.3% | N/A | -$3.56-747.6% | -$27.18-4081.5% |
| EPS (Diluted) | -$6.88 | N/A | -$0.91 | -$1.03 | -$29.90 | N/A | -$3.56 | -$27.18 |
| Diluted Shares (Avg) | 3M | N/A | 858,434 | 484,566 | 62,615 | N/A | 280,318 | 25,312 |
NAOV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'25 | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'24 | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $39.9M-9.6% | $41.1M+1033.2% | $54.4M+1061.5% | $51.5M+803.8% | $44.1M+607.4% | $3.6M-45.6% | $4.7M-36.4% | $5.7M+48.7% |
| Current Assets | $6.2M+60.6% | $7.3M+118.3% | $10.0M+128.8% | $6.9M+28.0% | $3.9M-35.1% | $3.3M-48.7% | $4.4M-38.9% | $5.4M+49.0% |
| Cash & Equivalents | $2.2M+291.4% | $4.2M+461.7% | $7.0M+432.6% | $4.0M+85.7% | $571K-78.9% | $752K-77.1% | $1.3M-65.5% | $2.2M+757.7% |
| Inventory | $2.3M+12.2% | $2.3M+6.7% | $2.2M-0.3% | $2.2M-9.3% | $2.0M-22.0% | $2.2M-19.8% | $2.3M-29.2% | $2.4M-21.9% |
| Accounts Receivable | $332K-7.3% | $289K+194.9% | $252K-56.6% | $115K-76.5% | $358K-0.6% | $98K-69.2% | $580K+1712.5% | $489K+588.7% |
| Goodwill | $29.1M-14.2% | $29.1M | $38.6M | $38.6M | $33.9M | N/A | N/A | N/A |
| Total Liabilities | $7.9M-6.8% | $7.6M+154.1% | $11.9M+324.2% | $11.0M+285.5% | $8.4M+208.7% | $3.0M+11.8% | $2.8M+5.2% | $2.9M+7.1% |
| Current Liabilities | $6.9M-16.3% | $6.7M+144.7% | $11.6M+361.9% | $6.5M+156.0% | $8.2M+237.9% | $2.7M+10.9% | $2.5M+5.4% | $2.6M+7.8% |
| Non-Current Liabilities | $991K+330.9% | $967K+245.4% | $275K-4.8% | $4.5M+1392.3% | $230K-24.3% | $280K+20.7% | $289K+3.6% | $299K+1.0% |
| Long-Term Debt | N/A | N/A | N/A | N/A | $1.3M | N/A | N/A | N/A |
| Total Equity | $32.0M-10.3% | $33.5M+5242.4% | $42.5M+2168.4% | $40.5M+1324.7% | $35.7M+918.1% | $627K-84.3% | $1.9M-60.1% | $2.8M+143.9% |
| Retained Earnings | -$112.1M-55.1% | -$90.5M-29.6% | -$76.9M-12.4% | -$76.0M-12.8% | -$72.3M-8.4% | -$69.8M-5.6% | -$68.4M-4.7% | -$67.4M-4.4% |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
NAOV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'25 | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'24 | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.3M-221.1% | -$2.7M-388.3% | -$2.0M-135.6% | -$3.4M-511.8% | -$1.3M-132.0% | -$548K-11.6% | -$836K-22.6% | -$553K+55.0% |
| Depreciation & Amortization | $217K+1105.6% | N/A | N/A | N/A | $18K | N/A | N/A | N/A |
| Capital Expenditures | $17K+240.0% | $23K | $28K | $4K+100.0% | $5K+400.0% | $0 | $0 | $2K |
| Free Cash Flow | -$4.3M-221.1% | -$2.7M-392.5% | -$2.0M-139.0% | -$3.4M-510.3% | -$1.3M-132.4% | -$548K-11.6% | -$836K-22.6% | -$555K+54.8% |
| Investing Cash Flow | -$17K-111.9% | -$23K | -$28K | -$4K-100.0% | $143K+14400.0% | $0 | $0 | -$2K |
| Financing Cash Flow | $2.3M+122.9% | -$34K | $4.9M+18322.2% | $6.8M | $1.1M | $0 | -$27K-100.6% | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
NAOV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'25 | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'24 | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -8.4%-44.4pp | -118.6% | 26.2%-9.2pp | -7.1%-59.5pp | 36.0%-36.1pp | 63.7%+1.1pp | 35.4%-40.8pp | 52.4%-21.1pp |
| Operating Margin | -568.3% | -4748.1% | -311.2% | -804.9% | -180.7% | -308.6% | -258.0% | -82.5% |
| Net Margin | -585.3% | -4119.2% | 70.6% | -803.9% | -182.6% | -322.3% | -265.4% | -84.2% |
| Return on Equity | -11.9%-6.7pp | -38.4%+189.9pp | 1.2%+54.5pp | -9.8%+14.4pp | -5.3%+11.5pp | -228.2%-207.8pp | -53.3%-37.8pp | -24.2%+68.0pp |
| Return on Assets | -9.6%-5.3pp | -31.3%+8.2pp | 0.9%+22.3pp | -7.7%+4.4pp | -4.2%+5.2pp | -39.4%-27.2pp | -21.3%-11.4pp | -12.1%+15.9pp |
| Current Ratio | 0.90+0.4x | 1.09-0.1x | 0.86-0.9x | 1.05-1.1x | 0.47-2.0x | 1.22-1.4x | 1.74-1.3x | 2.11+0.6x |
| Debt-to-Equity | 0.25+0.2x | 0.23-4.6x | 0.28-1.2x | 0.27-0.7x | 0.04-0.7x | 4.79+4.1x | 1.50+0.9x | 1.00-1.3x |
| Asset Turnover | 0.020.0x | 0.01-0.1x | 0.01-0.1x | 0.01-0.1x | 0.02-0.1x | 0.12-0.1x | 0.080.0x | 0.14+0.1x |
| FCF Margin | -662.9% | -865.1% | -276.7% | -685.6% | -131.5% | -123.4% | -222.3% | -67.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NanoVibronix, Inc. NAOV | FY2025 | $2.6M | -$18.2M | N/A | $3.2M | 28/100 |
| Tivic Health Systems, Inc. TIVC | FY2025 | N/A | -$8.9M | N/A | $4.0M | — |
| VENUS CONCEPT INC VERO | FY2024 | $64.8M | -$47.0M | -72.5% | $2.1M | — |
| Nuwellis, Inc. NUWE | FY2025 | $8.3M | -$17.5M | N/A | $2.2M | 45/100 |
| Bone Biologics Corp BBLG | FY2025 | N/A | -$3.1M | N/A | $1.3M | — |
| Xylo Technologies Ltd. American XYLO | FY2024 | $29.9M | -$12.0M | -40.2% | $6.5M | 21/100 |
Where NanoVibronix, Inc. Ranks
Frequently Asked Questions
What is NanoVibronix, Inc.'s annual revenue?
NanoVibronix, Inc. (NAOV) reported $2.6M in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is NanoVibronix, Inc.'s revenue growing?
NanoVibronix, Inc. (NAOV) revenue declined by 0.2% year-over-year, from $2.6M to $2.6M in fiscal year 2025.
Is NanoVibronix, Inc. profitable?
No, NanoVibronix, Inc. (NAOV) reported a net income of -$18.2M in fiscal year 2025.
What is NanoVibronix, Inc.'s EBITDA?
NanoVibronix, Inc. (NAOV) had EBITDA of -$22.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is NanoVibronix, Inc.'s gross margin?
NanoVibronix, Inc. (NAOV) had a gross margin of 6.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is NanoVibronix, Inc.'s return on equity (ROE)?
NanoVibronix, Inc. (NAOV) has a return on equity of -54.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is NanoVibronix, Inc.'s free cash flow?
NanoVibronix, Inc. (NAOV) recorded an outflow of $9.4M in free cash flow during fiscal year 2025. This represents a -274.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NanoVibronix, Inc.'s operating cash flow?
NanoVibronix, Inc. (NAOV) recorded an outflow of $9.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are NanoVibronix, Inc.'s total assets?
NanoVibronix, Inc. (NAOV) had $41.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are NanoVibronix, Inc.'s capital expenditures?
NanoVibronix, Inc. (NAOV) invested $60K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does NanoVibronix, Inc. spend on research and development?
NanoVibronix, Inc. (NAOV) invested $1.8M in research and development during fiscal year 2025.
What is NanoVibronix, Inc.'s current ratio?
NanoVibronix, Inc. (NAOV) had a current ratio of 1.09 as of fiscal year 2025, which is considered adequate.
What is NanoVibronix, Inc.'s debt-to-equity ratio?
NanoVibronix, Inc. (NAOV) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is NanoVibronix, Inc.'s return on assets (ROA)?
NanoVibronix, Inc. (NAOV) had a return on assets of -44.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does NanoVibronix, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, NanoVibronix, Inc. (NAOV) held $4.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.4M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is NanoVibronix, Inc.'s Altman Z-Score?
NanoVibronix, Inc. (NAOV) has an Altman Z-Score of -4.59, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is NanoVibronix, Inc.'s Piotroski F-Score?
NanoVibronix, Inc. (NAOV) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NanoVibronix, Inc.'s earnings high quality?
NanoVibronix, Inc. (NAOV) reported a net loss of $18.2M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is NanoVibronix, Inc.?
NanoVibronix, Inc. (NAOV) scores 28 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.